Deep Dive: Deep Dive Into Sequential T-Cell Redirection Therapies

As T-cell redirection therapies such as CAR T-cell therapies and bispecific antibodies become more common in the clinical setting, questions remain on how these therapies can be combined and sequenced. Samir Parekh, MD, and colleagues from the Tisch Cancer Institute conducted research on the efficacy of T-cell redirection therapies used sequentially to treat patients with relapsed/refractory multiple myeloma. CGTLive sat down with Parekh to learn more about the study’s findings.